Tracer library / [211At]At-NaAt

[211At]At-NaAt

Also written as [At-211]NaAt

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 1

Thyroid cancer

What it is

Compound class: Sodium astatide (inorganic astatide salt, NaAt)
Target / mechanism: Sodium/iodide symporter (NIS) PMID 41765488
Clinical application: Targeted alpha therapy for refractory thyroid cancer resistant to conventional radioiodine therapy PMID 38619655
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
COSMiC-Mini NMP Business Support	custom manifold	none	40 ± 3% decay-corrected	97 ± 1%	—	38619655 2024 EJNMMI Radiopharm Chem the automated dry distillation system COSMiC-Mini VTRSC2 (Nihon Mediphysics Business Support, Hyogo, Japan) - radiochemical yield of [211At]NaAt were 78.8 ± 6.0 MBq and 40 ± 3%, respectively

Need this precursor?We can point you to suppliers for [211At]At-NaAt, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38619655: 'to conduct an investigator-initiated clinical trial'. | Stage 30 (2026-09-18): Stage was 'investigational product for investigator-initiated clinical trial'; normalised to 'Clinical research', original wording kept here.